Literature DB >> 17057549

Changes in performance over time on the Bayley Scales of Infant Development II when administered to infants at high risk of developmental disabilities.

Karen Koseck1, Susan R Harris.   

Abstract

PURPOSE: The purpose of this study was to analyze changes in performance over time on the Bayley Scales of Infant Development II (BSID-II) in a sample of infants at high risk of developmental disabilities.
METHODS: Cognitive and motor performance of 53 infants, 34 with prenatal drug exposure (DE group) and 19 with perinatal medical concerns (PMC group), was measured at under one year of age (mean = 6.99 months) and again at 17-22 months of age (mean = 18.24 months). Changes in performance on both the Mental and Motor Scales over time were analyzed.
RESULTS: Over time, cognitive performance decreased for both groups (p < 0.05). Rate of change in motor performance increased for the PMC group and decreased for the DE group (p < 0.01).
CONCLUSIONS: Developmental changes over time should be studied separately for infants prenatally exposed to drugs and infants with perinatal medical concerns. Longer term follow-up with several repeat assessments would be desirable.

Entities:  

Year:  2004        PMID: 17057549     DOI: 10.1097/01.PEP.0000145910.38982.B5

Source DB:  PubMed          Journal:  Pediatr Phys Ther        ISSN: 0898-5669            Impact factor:   3.049


  3 in total

Review 1.  Forty Years of Assessing Neurodevelopmental and Behavioral Effects of Prenatal Alcohol Exposure in Infants: What Have We Learned?

Authors:  Laura Garrison; Sarah Morley; Christina D Chambers; Ludmila N Bakhireva
Journal:  Alcohol Clin Exp Res       Date:  2019-07-03       Impact factor: 3.455

2.  Statistical versus clinical significance for infants with brain injury: reanalysis of outcome data from a randomized controlled study.

Authors: 
Journal:  Clin Nurs Res       Date:  2009-03-10       Impact factor: 2.075

3.  Bayley-III motor scale and neurological examination at 2 years do not predict motor skills at 4.5 years.

Authors:  Nataliia Burakevych; Christopher Joel Dorman Mckinlay; Jane Marie Alsweiler; Trecia Ann Wouldes; Jane Elizabeth Harding
Journal:  Dev Med Child Neurol       Date:  2016-08-20       Impact factor: 5.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.